Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from OncoSil Medical
- Australian Manufacturing Facility Achieves ISO 13485
- OSL Secures $5.6 million from Major Institutional Investors
- OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
- OncoSil Medical Completes Manufacturing Validation
- OncoSil Medical Files for FDA Approval
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical